APG Asset Management N.V. Has $306.23 Million Position in Balchem Co. (NASDAQ:BCPC)

APG Asset Management N.V. lessened its holdings in shares of Balchem Co. (NASDAQ:BCPC) by 29.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,945,474 shares of the basic materials company’s stock after selling 822,904 shares during the period. Balchem makes up 0.9% of APG Asset Management N.V.’s portfolio, making the stock its 23rd biggest position. APG Asset Management N.V. owned approximately 5.98% of Balchem worth $306,231,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BCPC. Westside Investment Management Inc. bought a new position in shares of Balchem in the third quarter valued at $27,000. R Squared Ltd bought a new stake in Balchem in the 4th quarter valued at about $29,000. Federated Hermes Inc. bought a new stake in shares of Balchem during the 4th quarter worth approximately $33,000. Wilmington Savings Fund Society FSB bought a new position in Balchem in the third quarter valued at about $35,000. Finally, Venturi Wealth Management LLC bought a new stake in shares of Balchem during the fourth quarter worth $95,000. 87.91% of the stock is owned by institutional investors and hedge funds.

Balchem Trading Down 1.1 %

Balchem stock opened at $154.13 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.99 and a quick ratio of 1.16. Balchem Co. has a one year low of $137.69 and a one year high of $186.03. The stock has a market capitalization of $5.01 billion, a PE ratio of 39.22, a price-to-earnings-growth ratio of 4.41 and a beta of 0.75. The business’s fifty day moving average is $165.30 and its 200 day moving average is $168.79.

Balchem (NASDAQ:BCPC) last posted its earnings results on Friday, February 21st. The basic materials company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.11 by ($0.08). The company had revenue of $240.00 million for the quarter, compared to analysts’ expectations of $239.96 million. Balchem had a net margin of 13.47% and a return on equity of 11.37%. On average, sell-side analysts predict that Balchem Co. will post 4.64 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BCPC. Sidoti upgraded Balchem to a “hold” rating in a report on Tuesday, February 25th. HC Wainwright reissued a “buy” rating and set a $190.00 target price on shares of Balchem in a research report on Monday, February 24th. Finally, StockNews.com cut shares of Balchem from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.